The C1GALT1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of the human A-549 lung adenocarcinoma cell line, providing a loss-of-function model for the core 1 ??1,3-galactosyltransferase (C1GALT1) gene. The polyclonal format yields a heterogeneous cell pool with target-gene disruption, well-suited for pooled functional screening and glycobiology applications.
A-549 is an adherent epithelial-like cell line derived from a 58-year-old Caucasian male with lung adenocarcinoma, serving as a model of alveolar type II epithelium. It is extensively used in respiratory biology, oncology, and pharmacological research due to its robust signaling characteristics and ease of genetic modification.
C1GALT1, together with its obligate chaperone C1GALT1C1 (Cosmc), catalyzes the transfer of galactose to GalNAc-O-Ser/Thr to form core 1 O-glycans (T-antigen) on glycoproteins such as MUC1, IgA1, Notch receptors, ??1 integrins, and CD44. Its transcription is positively regulated by SP1. Knockout of C1GALT1 ablates core 1 synthesis, resulting in truncated Tn antigen exposure, which disrupts glycoprotein stability, cell adhesion, and Notch signaling. This alteration mimics disease-relevant glycosylation defects observed in Tn syndrome, IgA nephropathy, and cancers with aberrant O-glycosylation.
In the A-549 background, C1GALT1 knockout enables the study of mucin-type O-glycosylation in lung adenocarcinoma epithelium. It provides a system to examine how Tn antigen accumulation affects key oncogenic processes such as MUC1-mediated signaling, integrin-dependent adhesion, and Notch pathway activity, thereby offering insights into glycosylation-dependent mechanisms of tumor progression and immune recognition.
Key applications include glycobiology of cancer, O-glycan biosynthesis, IgA nephropathy modeling, Notch signaling studies, and congenital disorders of glycosylation. Common assays involve lectin blotting with PNA and VVA, flow cytometry with lectins, MUC1 Western blot, RT-qPCR, cell adhesion assays, and Notch reporter assays. For additional product details, please contact Ascent Research.
